214 related articles for article (PubMed ID: 22971050)
1. Risk factors and outcome of HIV-associated idiopathic noncirrhotic portal hypertension.
Schouten JN; Van der Ende ME; Koëter T; Rossing HH; Komuta M; Verheij J; van der Valk M; Hansen BE; Janssen HL
Aliment Pharmacol Ther; 2012 Nov; 36(9):875-85. PubMed ID: 22971050
[TBL] [Abstract][Full Text] [Related]
2. The role of nucleoside and nucleotide analogues in nodular regenerative hyperplasia in HIV-infected patients: a case control study.
Cotte L; Bénet T; Billioud C; Miailhes P; Scoazec JY; Ferry T; Brochier C; Boibieux A; Vanhems P; Chevallier M; Zoulim F
J Hepatol; 2011 Mar; 54(3):489-96. PubMed ID: 21056493
[TBL] [Abstract][Full Text] [Related]
3. Association of noncirrhotic portal hypertension in HIV-infected persons and antiretroviral therapy with didanosine: a nested case-control study.
Kovari H; Ledergerber B; Peter U; Flepp M; Jost J; Schmid P; Calmy A; Mueller NJ; Muellhaupt B; Weber R;
Clin Infect Dis; 2009 Aug; 49(4):626-35. PubMed ID: 19589079
[TBL] [Abstract][Full Text] [Related]
4. Noncirrhotic portal hypertension associated with didanosine: a case report and literature review.
Chang HM; Tsai HC; Lee SS; Wann SR; Chen YS
Jpn J Infect Dis; 2012; 65(1):61-5. PubMed ID: 22274160
[TBL] [Abstract][Full Text] [Related]
5. Higher risk of hyperglycemia in HIV-infected patients treated with didanosine plus tenofovir.
García-Benayas T; Rendón AL; Rodríguez-Novóa S; Barrios A; Maida I; Blanco F; Barreiro P; Rivas P; González-Lahoz J; Soriano V
AIDS Res Hum Retroviruses; 2006 Apr; 22(4):333-7. PubMed ID: 16623636
[TBL] [Abstract][Full Text] [Related]
6. Severe toxicity associated with the combination of tenofovir and didanosine: case report and review.
Masiá M; Gutiérrez F; Padilla S; Ramos JM; Pascual J
Int J STD AIDS; 2005 Sep; 16(9):646-8. PubMed ID: 16176639
[TBL] [Abstract][Full Text] [Related]
7. The development of hepatoportal sclerosis and portal hypertension due to didanosine use in HIV.
Schiano TD; Uriel A; Dieterich DT; Fiel MI
Virchows Arch; 2011 Feb; 458(2):231-5. PubMed ID: 21057809
[TBL] [Abstract][Full Text] [Related]
8. Idiopathic noncirrhotic portal hypertension is associated with poor survival: results of a long-term cohort study.
Schouten JN; Nevens F; Hansen B; Laleman W; van den Born M; Komuta M; Roskams T; Verheij J; Janssen HL
Aliment Pharmacol Ther; 2012 Jun; 35(12):1424-33. PubMed ID: 22536808
[TBL] [Abstract][Full Text] [Related]
9. Metabolic and anthropometric changes one year after switching from didanosine/stavudine to tenofovir in HIV-infected patients.
Claas GJ; Jülg B; Goebel FD; Bogner J
Eur J Med Res; 2007 Feb; 12(2):54-60. PubMed ID: 17369118
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of histological features of idiopathic noncirrhotic portal hypertension in general population: a retrospective study of incidental liver biopsies.
Zuo C; Chumbalkar V; Ells PF; Bonville DJ; Lee H
Hepatol Int; 2017 Sep; 11(5):452-460. PubMed ID: 28597108
[TBL] [Abstract][Full Text] [Related]
11. Pancreatic toxic effects associated with co-administration of didanosine and tenofovir in HIV-infected adults.
Martínez E; Milinkovic A; de Lazzari E; Ravasi G; Blanco JL; Larrousse M; Mallolas J; García F; Miró JM; Gatell JM
Lancet; 2004 Jul 3-9; 364(9428):65-7. PubMed ID: 15234858
[TBL] [Abstract][Full Text] [Related]
12. Didanosine-associated toxicity: a predictable complication of therapy with tenofovir and didanosine?
Masiá M; Gutiérrez F; Padilla S; Ramos JM; Pascual J
J Acquir Immune Defic Syndr; 2004 Apr; 35(4):427-8. PubMed ID: 15097160
[No Abstract] [Full Text] [Related]
13. Fatal portal hypertension, liver failure, and mitochondrial dysfunction after HIV-1 nucleoside analogue-induced hepatitis and lactic acidaemia.
Carr A; Morey A; Mallon P; Williams D; Thorburn DR
Lancet; 2001 May; 357(9266):1412-4. PubMed ID: 11356442
[TBL] [Abstract][Full Text] [Related]
14. Acute onset of pancreatitis with concomitant use of tenofovir and didanosine.
Kirian MA; Higginson RT; Fulco PP
Ann Pharmacother; 2004 Oct; 38(10):1660-3. PubMed ID: 15340130
[TBL] [Abstract][Full Text] [Related]
15. Short-term safety and tolerability of didanosine combined with high- versus low-dose tenofovir disproxil fumarate in ambulatory HIV-1-infected persons.
Young B; Weidle PJ; Baker RK; Armon C; Wood KC; Moorman AC; Holmberg SD;
AIDS Patient Care STDS; 2006 Apr; 20(4):238-44. PubMed ID: 16623622
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of once-daily didanosine, tenofovir and nevirapine as a simplification antiretroviral approach.
Negredo E; Moltó J; Muñoz-Moreno JA; Pedrol E; Ribera E; Viciana P; Galindos MJ; Miralles C; Burger D; Rodriguez Fumaz C; Puig J; Gel S; Rodríguez E; Videla S; Ruiz L; Clotet B
Antivir Ther; 2004 Jun; 9(3):335-42. PubMed ID: 15259896
[TBL] [Abstract][Full Text] [Related]
17. [Non-cirrhotic portal hypertension associated with didanosine: An unusual cause of gastrointestinal bleeding].
Gómez-Rubio J; Bárcena-Atalaya AB; Macías-García L; Lozano de León-Naranjo F
Med Clin (Barc); 2015 Jul; 145(1):45. PubMed ID: 25510631
[No Abstract] [Full Text] [Related]
18. Risk factors for CD4 lymphopenia in patients treated with a tenofovir/didanosine high dose-containing highly active antiretroviral therapy regimen.
Lacombe K; Pacanowski J; Meynard JL; Trylesinski A; Girard PM
AIDS; 2005 Jul; 19(10):1107-8. PubMed ID: 15958845
[TBL] [Abstract][Full Text] [Related]
19. Genetic determinants of idiopathic noncirrhotic portal hypertension in HIV-infected patients.
Vispo E; Cevik M; Rockstroh JK; Barreiro P; Nelson M; Scourfield A; Boesecke C; Wasmuth JC; Soriano V;
Clin Infect Dis; 2013 Apr; 56(8):1117-22. PubMed ID: 23315321
[TBL] [Abstract][Full Text] [Related]
20. Upper gastrointestinal bleeding may unmask didanosine-associated portal hepatopathy in HIV/HCV co-infected patients.
Vispo E; Maida I; Barreiro P; Moreno V; Soriano V
HIV Clin Trials; 2008; 9(6):440-4. PubMed ID: 19203910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
